Preeclampsia Therapeutics Market

How big is Preeclampsia Therapeutics Market in 2026?

USD 606.9 million in 2026 and USD 1239.3 million by 2036 at a 7.4% CAGR

Sales of preeclampsia therapeutics are projected to expand at 7.4% CAGR from 2026 to 2036, driving the valuation from USD 606.9 million in 2026 and USD 1239.3 million through 2036, supported by risk-based prophylaxis and monitored treatment. The World Health Organization reported in December 2025 that hypertensive disorders caused about 16% of maternal deaths worldwide in 2023, equivalent to roughly 42,000 deaths. The burden keeps treatment embedded in routine maternity planning and links therapeutic demand with preterm birth prevention and management. Commercial growth depends on earlier identification and hospital access that moves unstable patients into monitored care.

United States hospital systems combine a large maternity base with access to trial sites and biomarker testing. Japanese care pathways operate with fewer births but rely on closely monitored specialist services that can support higher treatment intensity per diagnosed case. Acute management still requires an infusion pump, repeated blood pressure checks, reflex assessment, and rapid delivery capability if maternal status worsens. DiaMedica Therapeutics reported in August 2025 that a USD 30.1 million private placement extended its cash runway and supported faster work on its preeclampsia program. Investment of that scale shows why disease-targeted candidates require more capital than established generic medicines. Wider use of pregnancy wearable devices may improve referral timing, but hospital access remains the decisive operational link between detection and treated revenue.

Key Takeaways of Preeclampsia Therapeutics Market

• Demand for preeclampsia therapeutics is driven by maternity systems identifying hypertensive risk early and keeping essential medicines available at the point of care, supported by broader prophylaxis and acute management across formal maternity pathways.
• By drug class, antihypertensives hold the leading share at 43.4% in 2026, attributable to their use across mild monitoring plus severe and postpartum blood-pressure control.
• Mild cases are the dominant severity segment, holding 42.9% share in 2026, owing to the larger monitored population before severe complications develop.
• Prophylaxis accounts for 53.3% treatment-setting share in 2026, underpinned by aspirin use among the broad population of pregnancies with recognized risk factors.
• Hospitals lead end-user demand at 66.7% share in 2026, shaped by the monitoring and emergency capabilities required for acute treatment.
• Japan, the United States, and Germany record CAGRs of 8.1%, 7.9%, and 7.4% respectively through 2036, while the United Kingdom and South Korea follow different growth paths shaped by distinct birth volumes and specialist referral systems.
• Competition centers on Pfizer, Fresenius Kabi, Comanche Biopharma, DiaMedica Therapeutics, and MirZyme Therapeutics, with vendors differentiating through established magnesium sulfate hospital supply versus investigational siRNA, vascular, and early-stage pipeline candidates.

Analyst Perspective

The commercial ceiling on preeclampsia treatment isn't clinical need but pricing structure: generic magnesium sulfate and low-dose aspirin keep acute and preventive care accessible, yet their low unit cost means revenue growth depends far more on screening coverage and diagnosis rates than on any single branded product gaining share. Prophylaxis captures the largest treatment-setting share precisely because it reaches pregnancies before symptoms appear, but that population-wide reach only converts to real volume if risk assessment happens early enough in antenatal care to start aspirin by the recommended 20-week threshold. Disease-targeted candidates like Comanche's siRNA program face a narrower commercial bar than typical drug launches, since any efficacy signal has to clear a strict double test of extending pregnancy safely while doing no harm to the fetus, not just outperforming placebo on a single endpoint.

-Anurag Sharma, Principal Analyst at Future Market Insights

How is the Preeclampsia Therapeutics Market segmented?

The preeclampsia therapeutics industry is segmented by drug class, severity, treatment setting, end user, and region.

The segmentation framework separates medicines by clinical purpose and by the point in care where revenue is generated. Drug-class analysis covers antihypertensives and magnesium sulfate together with antiplatelet prophylaxis and emerging disease-targeted candidates. Severity divides monitored mild disease from severe, early-onset, and late-onset cases with different treatment intensity. Treatment-setting analysis distinguishes prophylaxis from acute management and postpartum care across different points in the pregnancy pathway. End-user analysis separates hospitals from specialty obstetrics clinics because hospital teams can provide intensive monitoring and emergency delivery that smaller outpatient facilities cannot support. Regional analysis compares birth volumes with referral systems and purchasing capacity to explain why treatment revenue differs across countries. The resulting structure links established medicines with the broader magnesium sulfate supply base without treating diagnostic revenue as therapeutic sales.

What supports demand for antihypertensives within the drug class category?

Blood-pressure control is required across the clinical spectrum because hypertension is the defining maternal sign that treatment teams must stabilize. The World Health Organization reported in December 2025 that preeclampsia is diagnosed after 20 weeks with blood pressure of at least 140/90 mm Hg and proteinuria of at least 0.3 grams in 24 hours. The threshold creates recurring medicine use and connects obstetric care with treatment-resistant hypertension management in severe cases that need rapid escalation.

• In 2026, Antihypertensives are projected to account for 43.4% share, attributable to their use across mild monitoring plus severe and postpartum blood-pressure control. Hospital formularies commonly require several agents because clinicians must match treatment to maternal status and avoid medicines that are unsuitable during pregnancy.
• Maternity physicians draw on antihypertensives because uncontrolled blood pressure can accelerate maternal complications and force urgent delivery decisions. Purchase activity therefore follows admission volume, treatment protocols, and pharmacy readiness rather than a single branded product. Reliable stock matters most in referral hospitals that receive unstable patients from smaller maternity units.

How does mild preeclampsia shape demand within the severity category?

Mild disease creates a broad monitored population across pregnancies that have not developed seizures, organ injury, or severe blood-pressure elevation. The World Health Organization reported in December 2025 that preeclampsia affects 3% to 8% of women who give birth worldwide. The incidence range supports repeated assessment and outpatient follow-up across maternity systems with different screening capacity and referral access. The care pathway increasingly overlaps with women digital health solutions that help maternity teams review blood-pressure readings between scheduled visits.

• By severity, mild cases are estimated to hold 42.9% share in 2026, owing to the number of pregnancies managed before severe features appear. Revenue comes from prophylaxis and blood-pressure medicines together with laboratory follow-up and repeated clinical review. Therapeutic sales per case remain below the revenue generated during severe hospital admissions that require intensive care.
• Obstetric clinics focus on mild cases because timely monitoring can identify worsening blood pressure and reduce delayed referrals into emergency care. Medicine demand rises through protocol-based refills, risk-adjusted aspirin use, and continued monitoring across community and specialist maternity services. The commercial constraint is that many mild cases require observation rather than intensive drug treatment, which keeps revenue per patient below severe disease.

What makes prophylaxis central to the treatment setting category?

Prophylaxis begins before symptoms appear and therefore reaches a wider pregnancy population than acute treatment. The World Health Organization stated in December 2025 that women at risk should receive low-dose aspirin by 20 weeks of pregnancy or at the start of antenatal care. The recommendation makes risk screening commercially relevant because medicine use depends on enrollment early enough to begin prophylaxis. Preventive therapy belongs alongside prenatal nutrition in the wider antenatal pathway, although nutrition products remain outside prescription prophylaxis revenue.

• Prophylaxis is forecast to represent 53.3% share in 2026, underpinned by the broad population of clinically eligible pregnancies considered for risk-based aspirin. The setting captures many more treatment days than acute management, even though individual prescriptions carry a low unit price and require careful risk selection.
• Maternal-fetal medicine teams favor prophylaxis because treatment can begin during routine antenatal care and avoid dependence on hospital admission. Demand depends on early risk assessment, patient adherence, and consistent prescribing across community and specialist services. Commercial expansion is therefore tied to screening coverage and prescribing consistency rather than higher prices for established low-dose medicines.

How do maternity teams evaluate sospitals within the end user category?

Hospitals control acute therapeutic revenue because severe preeclampsia can require intravenous medicines, seizure prevention, fetal surveillance, and urgent delivery. The World Health Organization reported in December 2025 that magnesium sulfate reduces the risk of eclampsia by more than half. The seizure-prevention benefit requires trained staff, infusion controls, and toxicity monitoring throughout the acute treatment episode. Hospital purchasing therefore covers the medicine together with infusion capacity, laboratory access, and emergency obstetric services.

• Hospitals are projected to hold 66.7% share in 2026, reinforced by specialist hospital control over severe admissions and monitored intravenous therapy. The share reflects treatment complexity rather than simple patient volume because specialist clinics refer unstable cases to facilities with operating rooms and neonatal support.
• Hospital pharmacy and obstetric teams purchase preeclampsia medicines under protocols that connect dosing with vital-sign checks and rapid escalation. Product selection depends on dependable supply, clear pregnancy labeling, and compatibility with existing infusion practice. A new therapy must fit those routines before clinical interest can convert into recurring hospital procurement and standard protocol use.

What are the drivers, restraints, and opportunities in the preeclampsia therapeutics market?

The market is projected to expand at 7.4% CAGR between 2026 and 2036, supported by risk-based prophylaxis; generic pricing limits revenue capture; disease-targeted candidates create a higher-value treatment path.

• Driver: Clinical development funding and regulatory pathways are moving disease-targeted candidates toward formal trials and broader pregnancy-specific evidence programs.
• Restraint: Generic antihypertensives and magnesium sulfate support access but restrict revenue per treated episode across established hospital protocols.
• Opportunity: Placental and vascular candidates can raise episode value if trials show safer pregnancy extension.

Expanding pregnancy-specific development teams is supporting market growth. Comanche Biopharma reported in December 2025 that it appointed a global research and development head and established senior oversight for its Australian operation. The leadership expansion supports a wider clinical program for CBP-4888 and reduces dependence on a single-country development plan. Broader antenatal reach through mobile clinics can increase identification, but commercial demand still depends on a medicine proving maternal benefit and acceptable fetal safety.

One of the factors limiting growth is the low price of established medicines combined with uneven access in lower-resource systems. The World Health Organization identified regulatory, manufacturing, pricing, procurement, supply-chain, and quality-assurance barriers during its May 2026 Global Pre-eclampsia Summit. Mature branded generics can preserve availability, yet they leave little room for revenue expansion without higher treatment volume. The constraint shifts commercial pressure toward dependable supply and hospital readiness rather than price increases across existing care.

A significant opportunity lies in therapies that improve vascular function or reduce disease-driving placental signals. MirZyme Therapeutics reported in December 2025 that MZe786 is a hydrogen-sulfide-releasing aspirin derivative developed to restore endothelial function and address vascular dysfunction in preeclampsia. The candidate remains investigational, but its mechanism shows how prevention could move beyond standard aspirin. Programs based on siRNA connect the market with the oligonucleotide API supply chain as clinical scale and manufacturing requirements increase.

Which country CAGRs are profiled in the Preeclampsia Therapeutics Market?

Country	CAGR
USA	7.9%
UK	6.3%
Germany	7.4%
Japan	8.1%
South Korea	7.1%

How do country-level CAGRs compare in the Preeclampsia Therapeutics Market?

The country comparison is compressed within 1.8 percentage points despite distinct maternity care models. Japan and the USA form a closely aligned upper pair through specialist intensity and hospital purchasing. Germany and South Korea occupy a compact middle group supported by concentrated referral capability. The UK sits outside that group because national protocols operate across a smaller treatment pool.

• Japan relies on specialist hospitals and careful monitoring to raise treatment intensity per identified pregnancy.
• The USA combines a broad birth cohort with trial infrastructure and high-acuity maternity networks.
• Germany supports monitored treatment through reimbursed hospitals and regional maternal-fetal referral centers across several regions.
• South Korea concentrates high-risk pregnancies in tertiary facilities that coordinate maternal and neonatal care.
• UK adoption follows national guidance and centralized purchasing across established antenatal screening pathways and specialist services.

Similar CAGRs do not imply equal revenue opportunities because birth volumes and severe-case referrals differ considerably. Market entry depends on pregnancy-specific safety evidence and dependable medicine access within monitored maternity settings. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

• United States maternity systems combine a large annual birth cohort with hospital networks that can support investigational therapy and high-acuity care. By 2036, the United States is projected to grow at 7.9% CAGR, driven by clinical trial infrastructure and consistent hospital purchasing. The National Center for Health Statistics reported 3,628,934 live births for 2024 in June 2026. The birth volume creates a substantial screening base even before the preeclampsia incidence range is applied to the population. Maternal-fetal medicine specialists can move complex cases into tertiary hospitals, where pharmacy committees evaluate dosing evidence and fetal exposure. Developers that produce clear pregnancy safety data are better placed to win trial sites and later formulary review.
• The United Kingdom uses national guidance and specialist obstetric referral to standardize treatment across a publicly funded care system. The Office for National Statistics reported 585,396 live births in England and Wales during May 2026 for the 2025 data year. Preeclampsia therapeutic demand in the United Kingdom is forecast to rise at 6.3% CAGR over the forecast period, owing to established antenatal screening and centralized medicine purchasing. Lower birth volume limits the addressable pool, yet consistent national protocols can support broad prophylaxis across eligible pregnancies. Companies entering the market need evidence that fits National Health Service pathways and demonstrates a practical budget impact for maternity services.
• Germany combines reimbursed hospital care with a dense network of obstetric services and regional referral centers. Destatis reported in July 2026 that 654,241 children were born in Germany during 2025. The declining birth base makes treatment intensity and accurate case identification substantially more important than simple volume growth. The German preeclampsia therapeutics sector is projected to record 7.4% CAGR during the forecast period, reinforced by structured clinical pathways and access to monitored treatment. Hospital pharmacies require dependable supply for established medicines, while developers need German trial partners that can document maternal and neonatal outcomes across regional specialist centers.
• Japanese maternity care places close attention on specialist monitoring and hospital-based management for pregnancies that develop hypertension. Adoption of preeclampsia therapeutics in Japan is estimated to expand at 8.1% CAGR through 2036, aided by concentrated clinical expertise and treatment intensity per identified case. The Ministry of Health, Labour and Welfare recorded 686,061 preliminary live births for 2024 in June 2025. A shrinking birth cohort reduces volume, but it raises the value of preventing severe maternal and neonatal complications. Market entry requires local dosing evidence and a supply model that serves specialist hospitals without relying on broad primary-care distribution.
• South Korea has a compact hospital system that can concentrate high-risk pregnancies in facilities with maternal and neonatal services. The Ministry of Data and Statistics reported in February 2026 that live births reached 254.5 thousand during 2025. Preeclampsia therapeutic sales in South Korea are forecast to expand at 7.1% CAGR by 2036, shaped by recent birth recovery and strong tertiary-care capability. The increase broadens the pregnancy base, although the annual cohort remains smaller than those recorded in larger countries. Pharmaceutical companies need partnerships with high-volume maternity hospitals and evidence that supports efficient protocol adoption within a concentrated procurement environment.

Who are the notable companies in the Preeclampsia Therapeutics Market?

The notable companies in the sector includes Pfizer, Fresenius Kabi, Comanche Biopharma, DiaMedica Therapeutics, and MirZyme Therapeutics.

The companies in the market include established hospital medicines and investigational therapies aimed at placental signals or maternal vascular dysfunction. Pfizer and Fresenius Kabi participate through magnesium sulfate products used to prevent seizures in preeclampsia. Comanche Biopharma, DiaMedica Therapeutics, and MirZyme Therapeutics are pursuing placental or vascular mechanisms that could extend treatment beyond blood-pressure control and delivery. Competitive progress is therefore measured through pregnancy-specific safety, regulatory access, trial execution, and hospital fit rather than sales scale alone. The funding and operational demands resemble those found across clinical trials, but fetal exposure and maternal urgency make this market harder to develop.

• Pfizer supplies a premixed magnesium sulfate in 5% dextrose injection whose United States prescribing information covers prevention of eclampsia in patients with preeclampsia. The label requires an intravenous infusion pump, serum magnesium assessment, and repeated clinical monitoring throughout treatment. Its market role rests on an established acute-care presentation rather than a disease-targeted preeclampsia pipeline.
• Fresenius Kabi maintains a magnesium sulfate injection monograph revised in May 2025 that covers anticonvulsant use for preeclampsia and eclampsia. The document specifies pregnancy use, blood-pressure monitoring, and shortest-duration treatment guidance for hospital teams during acute care. Its commercial position is tied to dependable injectable supply and hospital use within the jurisdictions covered by the product monograph.
• Comanche Biopharma is developing CBP-4888 as an siRNA medicine intended to reduce placental production of sFlt1 in preterm preeclampsia. Its current research program is designed around direct placental uptake and selective reduction of a disease-driving protein. Clinical execution remains the central value test because the program must establish maternal benefit, fetal safety, and practical hospital use.
• DiaMedica Therapeutics is studying DM199 as a recombinant protein that may improve vascular function and reduce blood pressure in preeclampsia. The development plan includes early-onset disease and multinational expansion across sites that can measure maternal and fetal outcomes. Commercial relevance depends on larger controlled studies that establish clinical benefit and clear fetal safety evidence.
• MirZyme Therapeutics maintains a maternal-health pipeline that includes MZe786 and additional therapeutic candidates for preeclampsia or fetal growth restriction. The portfolio combines therapeutic development with a separate companion diagnostic program for preeclampsia risk assessment in hospitals and clinics. Commercial progress depends on moving therapeutic programs through toxicology and clinical testing without allowing diagnostic activity to overlap with therapeutic revenue.

Competitive Benchmarking: Preeclampsia Therapeutics Market

Company	Acute-Care Medicine Relevance	Disease-Targeted Pipeline	Pregnancy-Specific Evidence	Geographic Reach
Pfizer	High	Low	High	United States
Fresenius Kabi	High	Low	High	Canada
Comanche Biopharma	Low	High	Medium	United States, United Kingdom, European Union, and Australia
DiaMedica Therapeutics	Low	High	Medium	United States, Canada, South Africa, and planned United Kingdom expansion
MirZyme Therapeutics	Low	Medium	Low	United Kingdom

Key Developments in the Preeclampsia Therapeutics Market

• In January 2025, Comanche Biopharma received an Innovation Passport from the United Kingdom Innovative Licensing and Access Pathway Steering Group for CBP-4888. The siRNA candidate targets sFlt1-mediated preterm preeclampsia and represents a defined biological approach rather than general blood-pressure control. The designation gives the program coordinated regulatory and health-technology access support, which can help the developer align evidence plans with eventual National Health Service use.
• In April 2025, Comanche Biopharma received European Medicines Agency orphan drug designation for CBP-4888 in sFlt1-mediated preterm preeclampsia. The agency recognized the condition as life-threatening and uncommon under European orphan criteria for medicine development and access support. The designation provides protocol assistance and fee reductions that reduce development friction during clinical planning. Possible market exclusivity improves the commercial case for a pregnancy-specific precision medicine with limited patient volume.
• In July 2025, DiaMedica Therapeutics reported positive interim Phase 2 results for DM199 in preeclampsia across the evaluated dose cohorts. The study groups showed statistically significant blood-pressure reductions, and the company reported no evidence of placental transfer. The interim findings support further study of a vascular treatment across pregnancy populations with different disease severity. Larger controlled trials remain necessary to establish clinical benefit and commercial value for routine maternity care.
• In March 2026, DiaMedica Therapeutics received a No Objection Letter from Health Canada for a Phase 2 study of DM199 in early-onset preeclampsia. The clearance allows the company to begin its planned Canadian trial and supports later expansion into the United States and United Kingdom. The program now moves from investigator-led evidence toward a broader regulatory development plan with country-specific trial requirements.

Key Players in the Preeclampsia Therapeutics Market

Established Acute-Care Medicine Suppliers

• Pfizer
• Fresenius Kabi

Disease-Targeted Therapy Developers

• Comanche Biopharma
• DiaMedica Therapeutics
• MirZyme Therapeutics

Preeclampsia Therapeutics Market - Report Scope

Coverage field	Report scope
Market breakdown	Drug class, severity, treatment setting, end user, and region.
Market Definition	The market covers medicines used to prevent or manage preeclampsia, including antihypertensives, magnesium sulfate, antiplatelet prophylaxis, and investigational disease-targeted therapies. The definition excludes diagnostic products and laboratory platforms from therapeutic revenue to prevent overlap with adjacent testing markets.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa.
Countries Covered	United States, United Kingdom, Germany, Japan, South Korea, and 30+ countries within the regional model.
Key Companies Profiled	Pfizer, Fresenius Kabi, Comanche Biopharma, DiaMedica Therapeutics, and MirZyme Therapeutics.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Preeclampsia Therapeutics Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Preeclampsia Therapeutics Market by Segments

Preeclampsia Therapeutics Market segmented by Drug Class:

• Antihypertensives
• Magnesium Sulfate
• Antiplatelet Agents
• Emerging Therapies, including sFlt1 inhibitors and placental or vascular modulators

Preeclampsia Therapeutics Market segmented by Severity:

• Mild
• Severe
• Early-onset
• Late-onset

Preeclampsia Therapeutics Market segmented by Treatment Setting:

• Prophylaxis
• Acute Management
• Postpartum Care

Preeclampsia Therapeutics Market segmented by End User:

• Hospitals
• Specialty Obstetrics Clinics

Preeclampsia Therapeutics Market by Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • United Kingdom
  • France
  • Rest of Western Europe
• Eastern Europe
  • Poland
  • Hungary
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Saudi Arabia
  • Other GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Research Sources and Bibliography

• World Health Organization. (2025, December 10). Pre-eclampsia.
• World Health Organization. (2026, May 5). Global pre-eclampsia summit.
• National Center for Health Statistics. (2026, June 9). Births: Final Data for 2024.
• Office for National Statistics. (2026, May 27). Births in England and Wales: 2025.
• Federal Statistical Office of Germany. (2026, July 1). Total fertility rate drops to 1.32 children per woman in 2025.
• Ministry of Health, Labour and Welfare. (2025, June). Vital Statistics in Japan (preliminary data of 2024).
• Ministry of Data and Statistics. (2026, February 25). Preliminary Results of Birth and Death Statistics in 2025.
• Pfizer. (n.d.). Magnesium Sulfate in 5% Dextrose Injection.
• Fresenius Kabi. (2025, May 14). Magnesium Sulfate Injection, USP.
• Comanche Biopharma. (n.d.). CBP-4888.
• Comanche Biopharma. (2025, January 30). Comanche Biopharma Awarded Innovation Passport Designation by the UK. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia.
• Comanche Biopharma. (2025, April 8). Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia.
• Comanche Biopharma. (2025, December 2). Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia.
• DiaMedica Therapeutics. (2025, July 17). DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer.
• DiaMedica Therapeutics. (2025, August 12). DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights.
• DiaMedica Therapeutics. (2026, March 5). DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia.
• MirZyme Therapeutics. (n.d.). Our pipeline.
• MirZyme Therapeutics. (2025, December 12). MirZyme Therapeutics Wins Institute of Physics Business Start Up Award 2025 for Transformative Innovation in Maternal Health.

This bibliography is provided for reader reference and is not exhaustive; the full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the preeclampsia therapeutics market in 2026 and 2036?
• Which clinical and health-system factors support a 7.4% CAGR from 2026 to 2036?
• Why do antihypertensives account for 43.4% share in 2026?
• How does mild disease influence therapeutic volume and revenue per patient?
• Why does prophylaxis represent 53.3% share in 2026?
• What gives hospitals 66.7% share of end-user revenue in 2026?
• How do country CAGRs differ across the United States, United Kingdom, Germany, Japan, and South Korea?
• Which verified companies supply established medicines or develop disease-targeted therapies?
• What evidence should maternity leaders assess before adopting an investigational preeclampsia therapy?